Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome.
Three cases of chronic fatigue syndrome (CFS) that followed acute parvovirus B19 infection were treated with a 5-day course of intravenous immunoglobulin (IVIG; 400 mg/kg per day), the only specific treatment for parvovirus B19 infection. We examined the influence of IVIG treatment on the production of cytokines and chemokines in individuals with CFS due to parvovirus B19. IVIG therapy led to clearance of parvovirus B19 viremia, resolution of symptoms, and improvement in physical and functional ability in all patients, as well as resolution of cytokine dysregulation.
Kerr
J R
JR
Department of Microbiology, Royal Brompton Hospital, Imperial College London, Sydney St, London SW3 6NP, United Kingdom. j.kerr@imperial.ac.uk
Cunniffe
V S
VS
Kelleher
P
P
Bernstein
R M
RM
Bruce
I N
IN
D000328:Adult; D015673:Fatigue Syndrome, Chronic / Q000628:therapy* / Q000821:virology; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010322:Parvoviridae Infections / Q000628:therapy*; D016732:Parvovirus B19, Human / Q000276:immunology*; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous